Hypertrophic cardiomyopathy

This study tests a minimally invasive procedure called SESAME for people with thickened heart muscle that blocks blood flow from the heart. The procedure uses a catheter to make a controlled slice in the muscle, aiming to relieve symptoms like shortness of breath. Researchers wil…

Researchers are testing whether adults with obstructive hypertrophic cardiomyopathy can safely taper off beta-blockers after their heart condition has stabilized on mavacamten. The trial enrolls 286 people aged 18 to 75 who have been on a stable dose of mavacamten and one beta-bl…

This phase 3 trial is testing whether an experimental drug called BHB-1893 works better than the standard beta-blocker metoprolol for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and blocks blood flow. The stu…

This study tests whether adjusting the dose of mavacamten based on heart pumping strength can further reduce the blockage of blood flow in people with obstructive hypertrophic cardiomyopathy. Participants are adults who have been on a stable mavacamten dose for at least 12 weeks …

This phase 2 trial tests an oral drug called Aom0304 in adults with hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The study includes people with both obstructive and non-obstructive forms. Participants receive different doses of Aom0304 for …

This study tests whether henagliflozin, a drug currently used for diabetes, can reduce scarring in the heart muscle of people with a type of hypertrophic cardiomyopathy (non-obstructive HCM). The trial will enroll 150 adults and use special PET scans to measure changes in scar ti…

This pilot study will test a new method to see how two pain medicines, naproxen and pregabalin, work in healthy adults. Up to 25 participants will receive each medicine and a placebo in random order. They will undergo several short, controlled pain tests, like a cold water hand b…

Researchers at University Health Network in Toronto are reviewing the records of 150 adults who had septal myectomy for hypertrophic obstructive cardiomyopathy. They compare intraoperative echocardiograms with predischarge echocardiograms to see how often moderate or worse mitral…

This study looks at people with obstructive hypertrophic cardiomyopathy — a condition where the heart muscle is abnormally thick and blocks blood flow. Researchers want to see if certain abnormalities in the mitral valve or its supporting structures affect how well the drug mavac…

This study will collect health information from 3000 people with hypertrophic cardiomyopathy (HCM) across multiple hospitals in China. The goal is to build a comprehensive database to understand how the disease is currently diagnosed and treated, and to identify factors that affe…

This study looks at how a person's genes affect their response to the heart drug mavacamten for obstructive hypertrophic cardiomyopathy. Researchers will collect DNA samples from 300 patients to see which genetic types respond best. The goal is to improve dosing safety and effect…

This study gathers information from 5,000 adults with hypertrophic cardiomyopathy, a condition where the heart muscle is too thick. Researchers will use heart MRI scans to look for scarring and build a better way to predict who is at risk of dying from the disease. The goal is to…

This study aims to find out why the heart medication mavacamten works better for some people with hypertrophic cardiomyopathy (a condition where the heart muscle is too thick) than for others. Researchers will look at participants' genes, including the specific gene causing their…

This study looks at whether a new medication (mavacamten) can improve the energy levels of the heart muscle in people with obstructive hypertrophic cardiomyopathy, a condition where the heart wall thickens and blocks blood flow. Researchers will use a special MRI scan to measure …